DANAHER CORPDHR
時価総額
$1628.2億
PER
ライフサイエンス機器・試薬の大手。質量分析装置やレーザー走査顕微鏡、抗体試薬などのプロテオミクス製品を展開。2023年12月に主要プロテオミクス企業を約56億ドルで買収。北米・欧州・アジア中心に約60カ国で展開。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net earnings | 1,793 | 2,172 | 2,392 | 2,695 | 2,598 | 3,357 | 2,554 | 2,492 | 2,651 | 3,008 | 3,646 | 6,433 | 7,209 | 4,764 | 3,899 |
| Less: earnings from discontinued operations, net of income taxes | - | - | - | - | - | - | - | - | - | 576 | - | 86 | - | 543 | - |
| Net earnings from continuing operations | - | 1,935 | 2,299 | 2,695 | 2,598 | 2,599 | 2,153 | 2,470 | 2,651 | 2,432 | 3,646 | 6,347 | 7,209 | 4,221 | 3,899 |
| Depreciation | 198 | 351 | 498 | 530 | 553 | 574 | 545 | 578 | 602 | 564 | 637 | 718 | 738 | 675 | 721 |
| Amortization of intangible assets | - | - | - | - | - | - | - | - | - | 625 | 1,138 | 1,450 | 1,484 | 1,491 | 1,600 |
| Amortization Of Inventory Step Up | - | - | - | - | - | - | - | - | - | - | 457 | 59 | - | 8 | 25 |
| Stock-based compensation expense | 88 | 96 | 110 | 118 | 121 | 139 | 130 | 139 | 151 | 159 | 187 | 218 | 336 | 306 | 288 |
| Investment losses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -57 |
| Impairment charges | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 265 |
| Change in deferred income taxes | -43 | -271 | -185 | -255 | -177 | 151 | 384 | 427 | 195 | 415 | -518 | 229 | 559 | 1,204 | 483 |
| Change in trade accounts receivable, net | 262 | 135 | 80 | 49 | 142 | 52 | 183 | 161 | 58 | 156 | 264 | 611 | 477 | -322 | -331 |
| Change in inventories | 166 | -162 | -70 | -63 | -51 | -120 | -9 | 27 | 143 | 22 | 123 | 502 | 486 | -185 | -147 |
| Change in trade accounts payable | 225 | 37 | 57 | 183 | 118 | 104 | 78 | -54 | 226 | 18 | 227 | 549 | 5 | -149 | 19 |
| Change in prepaid expenses and other assets | -71 | 111 | 100 | 120 | 126 | 87 | 62 | -4 | -90 | -48 | -102 | 4 | 78 | -419 | -274 |
| Change in accrued expenses and other liabilities | 210 | -139 | 147 | -89 | 178 | 118 | 263 | 313 | -9 | 405 | 145 | 139 | 76 | 34 | -486 |
| Total operating cash provided by continuing operations | - | 2,732 | 3,502 | 3,585 | 3,758 | 3,828 | 3,088 | 3,478 | 4,022 | 3,657 | 6,215 | 8,358 | 8,519 | 6,490 | 6,688 |
| Total operating cash provided by discontinued operations | - | -106 | -87 | - | - | -26 | 434 | - | - | 294 | -7 | - | - | 674 | - |
| Net cash provided by operating activities | 2,084 | 2,626 | 3,415 | 3,585 | 3,758 | 3,802 | 3,522 | 3,478 | 4,022 | 3,952 | 6,208 | 8,358 | 8,519 | 7,164 | 6,688 |
| Cash paid for acquisitions | 2,130 | 6,211 | 1,797 | 957 | 3,131 | 14,305 | 4,880 | 386 | 2,173 | 331 | 20,971 | 10,961 | 637 | 5,610 | 558 |
| Payments for additions to property, plant and equipment | 217 | 334 | 458 | 552 | 598 | 633 | 590 | 620 | 656 | 636 | 791 | 1,294 | 1,152 | 1,383 | 1,392 |
| Proceeds from sales of property, plant and equipment | 2 | 9 | - | - | - | - | - | 33 | 6 | 13 | 2 | 13 | 9 | 12 | 13 |
| Payments for purchases of investments | - | - | - | - | - | 87 | - | - | 149 | 241 | 342 | 934 | 523 | 172 | 331 |
| Proceeds from sales of investments | - | - | - | - | - | - | - | - | - | - | - | - | - | 61 | 253 |
| All other investing activities | - | - | -30 | 2 | -30 | -70 | -32 | 9 | - | -29 | -24 | -37 | -51 | -44 | -34 |
| Total cash used in investing activities from continuing operations | - | -6,522 | -2,225 | -552 | -3,444 | -14,912 | -5,173 | -843 | -2,949 | -1,166 | -21,239 | -12,987 | - | -7,048 | -1,981 |
| Total investing cash used in discontinued operations | - | -5 | - | - | - | -39 | -70 | - | - | -72 | - | - | - | -33 | - |
| Net cash used in investing activities | -2,289 | -5,847 | -1,888 | -552 | -3,444 | -14,951 | -5,243 | -843 | -2,949 | -1,238 | -21,239 | -12,987 | -2,234 | -7,081 | -1,981 |
| Proceeds from the issuance of common stock in connection with stock-based compensation | - | - | - | - | - | - | - | - | - | 130 | 153 | 86 | 31 | 68 | 162 |
| Payment of dividends | 52 | 61 | 86 | 52 | 228 | 354 | 400 | 378 | 433 | 527 | 615 | 742 | 818 | 821 | 768 |
| Net proceeds from (repayments of) borrowings (maturities of 90 days or less) | - | 854 | 196 | -763 | 312 | 3,511 | 2,218 | -3,778 | 66 | 2,802 | -4,637 | 2,265 | -723 | -1,006 | 5 |
| Repayments of borrowings (maturities longer than 90 days) | - | - | - | - | - | - | - | - | - | - | 5,933 | 1,186 | 965 | 620 | 1,674 |
| Distribution from discontinued operations | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,600 | - |
| Payments for repurchase of common stock | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5,979 |
| All other financing activities | - | - | - | - | -21 | -3 | -27 | -60 | -18 | -43 | -3 | -16 | -95 | -67 | -131 |
| Net cash (used in) provided by financing activities for continuing operations | - | - | - | - | - | - | 2,528 | -3,098 | -797 | 16,590 | 1,006 | 1,295 | - | 154 | -8,385 |
| Cash distributions to Veralto Corporation, net | - | - | - | - | - | - | -485 | - | - | -224 | - | - | - | -427 | - |
| Net cash used in financing activities | 117 | 2,089 | -388 | -1,606 | -218 | 9,050 | 2,043 | -3,098 | -797 | 16,366 | 1,006 | 1,295 | -2,570 | -273 | -8,385 |
| Effect of exchange rate changes on cash and equivalents | - | - | - | - | - | - | - | - | - | - | 148 | -115 | -306 | 59 | -108 |
| Net change in cash and equivalents | - | - | - | - | - | - | - | - | - | - | -13,877 | -3,449 | 3,409 | -131 | -3,786 |
| Distribution of noncash net assets to Veralto Corporation | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,674 | - |